Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals Inc. develops and commercializes biotechnology medicines for serious diseases across eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disease, neurological disease, hematologic conditions, infectious disease and rare disease. News about REGN commonly covers marketed products and pipeline programs such as EYLEA, EYLEA HD, Dupixent, Praluent, Libtayo, Kevzara, Otarmeni and investigational therapies developed through antibody, genetic medicine and RNA-based approaches.
Recurring company updates include financial results, FDA and European regulatory approvals, clinical trial data, label expansions, collaboration and licensing activity, product-access and pricing arrangements, share repurchase authorizations and corporate responsibility recognition. Regeneron's disclosures also frequently address its Sanofi collaboration around Dupixent and its use of proprietary technologies such as VelocImmune in drug discovery.
Rhea-AI Summary
The FDA has approved Dupixent (dupilumab) as the first targeted treatment for adults with bullous pemphigoid (BP), a rare skin disease affecting approximately 27,000 U.S. adults. The approval is based on the ADEPT Phase 2/3 trial results, where Dupixent showed significant improvements compared to placebo: 18.3% of patients achieved sustained disease remission vs 6.1%, 38.3% experienced meaningful itch reduction vs 10.5%, and patients required lower oral corticosteroid doses (2.8g vs 4.1g). BP primarily affects elderly patients, causing intense itching, painful blisters, and skin lesions. Dupixent is now approved for eight distinct diseases with type 2 inflammation, spanning skin, gut, and respiratory conditions. The FDA granted Priority Review and Orphan Drug Designation for this indication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
-
Rhea-AI Summary
Regeneron and Sanofi presented groundbreaking results from the EVEREST Phase 4 trial comparing Dupixent to Xolair in treating chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma. The study, involving 360 adults, demonstrated Dupixent's superiority across all primary and secondary endpoints. Key achievements include a 1.60-point greater reduction in nasal polyp size and an 8.0-point superior improvement in smell identification compared to Xolair. Dupixent also showed significant advantages in nasal congestion reduction, symptom severity, and quality of life measures. In asthma-related outcomes, Dupixent demonstrated a 150 mL improvement in lung function and better asthma control. The safety profiles were comparable, with adverse events reported in 64% of Dupixent patients versus 67% for Xolair, and serious adverse events at 2% and 4% respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
-
Rhea-AI Summary
Regeneron and Sanofi presented promising Phase 4 DISCOVER trial results for Dupixent in treating atopic dermatitis patients with skin of color at the 2025 RAD Conference. The trial, involving 120 patients (82% Black), showed significant improvements in disease severity and symptoms. Key findings at 24 weeks included: 76% of patients achieved ≥75% improvement in disease severity (EASI-75), 53% experienced meaningful itch reduction, and a 53% reduction in post-inflammatory hyperpigmentation. The percentage of patients very/extremely bothered by dry skin decreased from 78% to 18%. Safety results aligned with Dupixent's known profile, with a 42% adverse event rate. These results mark the first large-scale clinical trial of Dupixent in patients with darker skin tones, addressing an underserved population disproportionately affected by atopic dermatitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.94%
Tags
Rhea-AI Summary
Regeneron Pharmaceuticals has entered a strategic in-licensing agreement with Hansoh Pharmaceuticals for HS-20094, a dual GLP-1/GIP receptor agonist currently in Phase 3 testing. The deal grants Regeneron exclusive development and commercial rights outside China Mainland, Hong Kong, and Macau. The weekly injectable has shown promising results in over 1,000 patients, with data suggesting similarity to the only FDA-approved GLP-1/GIP receptor agonist. Regeneron will pay $80 million upfront, with potential additional payments up to $1.93 billion based on milestones, plus low double-digit royalties on global net sales. The acquisition aims to enhance Regeneron's obesity treatment portfolio, focusing on quality weight loss and muscle mass maintenance. The drug is currently undergoing Phase 3 trials for obesity in China and Phase 2b studies for diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals (REGN) reported interim Phase 2 COURAGE trial results evaluating combinations of semaglutide with muscle-preserving antibodies for obesity treatment. The study revealed that 35% of semaglutide-induced weight loss came from lean mass loss. When combined with trevogrumab (with/without garetosmab), the treatment preserved 50-80% of lean mass while enhancing fat loss compared to semaglutide alone. The triplet combination (semaglutide + trevogrumab + garetosmab) showed the highest fat loss (-25.4 lbs) and total weight loss (-30.0 lbs) but had significant safety concerns with a 28.3% discontinuation rate. The dual combination of semaglutide with trevogrumab demonstrated better tolerability while still providing meaningful lean mass preservation and enhanced fat loss. The trial's complete data will be available later in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals announced significant Phase 3 trial results for Libtayo (cemiplimab) in treating high-risk cutaneous squamous cell carcinoma (CSCC) post-surgery. The C-POST trial demonstrated remarkable efficacy, with Libtayo reducing disease recurrence or death risk by 68% compared to placebo. The drug showed 80% reduction in locoregional recurrence risk and 65% reduction in distant recurrence risk. After 24 months of follow-up, disease-free survival was 87% with Libtayo versus 64% with placebo. The safety profile was manageable, with 24% of Libtayo patients experiencing Grade ≥3 adverse events compared to 14% in the placebo group. Regulatory applications have been submitted in both the US and EU, positioning Libtayo as potentially the first immunotherapy to demonstrate significant benefit in high-risk CSCC in the adjuvant setting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
Rhea-AI Summary
Regeneron and Sanofi announced mixed results from two Phase 3 trials (AERIFY-1 and AERIFY-2) evaluating itepekimab for COPD in former smokers. AERIFY-1 met its primary endpoint, showing a significant 27% reduction in moderate/severe exacerbations compared to placebo at week 52. However, AERIFY-2 failed to meet the same endpoint, despite showing early benefits. The trials tested two dosing regimens (every two weeks and four weeks) added to standard therapy. Safety profiles were consistent with previous trials, with comparable adverse events between treatment and placebo groups. Both companies are reviewing the data and will discuss next steps with regulatory authorities. The trials were affected by lower-than-expected exacerbation rates, possibly due to the COVID-19 pandemic impact on enrollment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.01%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals (NASDAQ: REGN) announced promising initial results from their Phase 1b LINKER-MM2 trial evaluating linvoseltamab combinations with proteasome inhibitors for relapsed/refractory multiple myeloma. The study tested two combinations:
1. Linvoseltamab + Carfilzomib:
- 90% objective response rate (19/21 patients)
- 76% complete response rate
- 87% probability of maintaining response at 12 months
- 83% progression-free probability at 12 months
2. Linvoseltamab + Bortezomib:
- 85% objective response rate (17/20 patients)
- 50% complete response rate
Both combinations showed manageable safety profiles, with neutropenia, cytokine release syndrome, and thrombocytopenia as common side effects. Linvoseltamab is already approved in the EU for R/R multiple myeloma, with FDA review expected by July 10, 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
-
Rhea-AI Summary
Viz.ai has announced a multi-year partnership with Sanofi (SNY) and Regeneron (REGN) to develop and evaluate an AI-powered workflow solution for Chronic Obstructive Pulmonary Disease (COPD). The collaboration will focus on deploying the Viz COPD module, which uses electronic health record (EHR) data and artificial intelligence to improve detection and management of high-risk COPD patients.
The solution will be implemented across Viz.ai's network of over 1,700 hospitals and health systems, reaching more than 60,000 healthcare providers. COPD, affecting an estimated 392 million people globally and ranking as the fourth leading cause of death worldwide, remains underprioritized and undertreated. The AI-powered system will screen and triage patients using natural language processing, aligning with established clinical guidelines to identify high-risk individuals requiring follow-up care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
Rhea-AI Summary
Regeneron Pharmaceuticals (NASDAQ: REGN) has won the bankruptcy auction to acquire 23andMe's core assets for $256 million. The acquisition includes 23andMe's Personal Genome Service, Total Health and Research Services business lines, and its Biobank. The deal, expected to close in Q3 2025, excludes 23andMe's Lemonaid Health business. 23andMe will operate as a wholly owned subsidiary of Regeneron, maintaining its consumer genetics services uninterrupted. Regeneron, which has experience managing genetic data from nearly 3 million participants, commits to protecting customer privacy and data security through oversight by a court-appointed Customer Privacy Ombudsman. The acquisition aims to strengthen Regeneron's genetics-guided research and drug development capabilities while preserving 23andMe's mission in personal genomics services.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
FAQ
What is the current stock price of Regeneron Pharmaceuticals (REGN)?
The current stock price of Regeneron Pharmaceuticals (REGN) is $723.41 as of May 12, 2026.
What is the market cap of Regeneron Pharmaceuticals (REGN)?
The market cap of Regeneron Pharmaceuticals (REGN) is approximately 74.7B.